GlaxoSmithKline Pharmaceuticals Ltd

drsastry@firstcallindia.com



Glaxo	Smithkine Pharma	ceuti	cais Lu	a	
C.M.P: Rs.1750.00	Target Price: Rs.1925.00				
				5	
1 Year Comparat 200 180 160 140 120 100 80 Mar 09 Jun 09 Aug GSK PHARMA Stock Data Sector Face Value 52 wk. High/Low (Rs Volume (2 wk. Avg.)) BSE Code Market Cap Share Holding Pat	Pharma Sector Rs.10.00 s.) Rs.1785.00/1060.0 4211 500660 148225.00	i s t f f I i c c c a i i c c c a i f f f i f i f i f i f i f i f i f i	 GSK Pharma is in the domestic subsidiary of the the world's second with an R&D wather The company of the for a phase of Laboratories. The company has a pharmaceutic it has got very gong the Cervarix vaccine Glaxo SmithKling at launching promecta, used platelet count, i The company in government to treating the popularly known The topline and is expected to go over 2008 to 20 		
17% 17% 15%	As on Dec.09 Promoters FIIs DIIs Non institutions				
		Fin	ancials	C	
		Net	Sales	189	
V.S.R. Sastry Equity Research Desk		EB	IDTA	692	
vsrsastry@firstcallindiaequity.com		PA'	Г	504	
Dr. V.V.L.N. Sastry Ph.D. Chief Research Officer		EP	5	59	

Firstcall Research

(KPO Division Of Firstobject Technologies Ltd.)

March 29, 2010

SYNOPSIS

- the largest pharma company c pharma market. It is a 51% he US\$ 46 bn Glaxo Group, ond-largest pharma company archest of US\$ 6.8 bn.
- has emerged as frontrunner d buy-in to Dr Reddy`s
- as introduced 3 vaccines and cal products in 9MCY09 and good response for Rotarix and e.
- ine Pharmaceutical is looking its patented medicine d in treatment of depleted in India.
- is obtaining a nod from the market its patented drug for contagious H1N1 virus, n as swine flu.
- d bottomline of the company row at a CAGR of 12% & 12%)11E.

			/
Financials	CY09	CY10E	CY11E
Net Sales	18910.90	20801.99	23298.23
EBIDTA	6929.40	7677.72	8585.81
PAT	5048.80	5605.07	6253.83
EPS	59.61	66.18	73.84
P/E	29.36	26.44	23.70

Ι R S Т С A L L R Ε S Ε Α R

F

C

Η

Financials	Dec08	Dec09	% Change
Net sales	3748.70	4498.80	20.01
РАТ	891.60	1067.20	19.69
EPS	10.53	12.60	19.69

* Board recommends Dividend

The company has approved a Dividend of Rs. 30 per equity share (Previous year Rs. 22 per equity share and a special additional Dividend of Rs. 18 per equity share).

✤ GSK to launch 'promecta' in India

GSK is looking at launching its patented medicine promecta, used in treatment of depleted platelet count, in India by this year-end or early next year. The company is looking to launch promecta in the Indian market in the fourth quarter of this year or in the first quarter of next year.

Net Sales and PAT of the company are expected to grow at a CAGR of 12% and 12% over 2008 to 2011E respectively.

Investment Rationale

GlaxoSmithKline eyes Dr Reddy`s Laboratories

The company has emerged as frontrunner for a phased buy-in to Dr Reddy's Laboratories. A transaction could spark a fresh wave of foreign deals in India's drugs sector. While nothing is finalized, one possibility is that Glaxo will take a 20% stake in Dr Reddy's Holdings, a family vehicle that in turn owns 23.2% of the drug maker. It is believed that this would give Glaxo a stake of just under

5%, worth around USD 165 million. But the British company could also get right of first refusal on the family`s remaining holding.

GSK's Cervarix blocks cervical cancer virus

The US Food and Drug Administration (USFDA) have announced that Cervarix from Glaxo Smith Kline (GSK) was effective in blocking the cervical cancer virus. The vaccine blocked the Human Papilloma Virus (HPV) about 93% of the time with some minor side effects. The agency is going to consult a team of professionals to seek their opinion on whether to approve the vaccine for female consumers falling in the age group of 10-25 years.

If the company receives approval for Cervarix then it will end the two years wait of the British drug-maker to introduce this vaccine in American markets. The vaccine has already been approved in around 100 countries across the globe.

Valuation

At the current market price of Rs.1750.00, the stock trades at a P/E of 26.44x and 23.70x for CY10E and CY11E respectively. Earning per share (EPS) of the company for the earnings of CY10E and CY11E is seen at Rs.66.18 and Rs.73.84 respectively for equity share of Rs.10.00 each. On the basis of EV/EBDITA, the stock trades at 19.31x and 17.26x for CY10E and CY11E respectively. Price to Book Value of the stock is expected to be at 6.39x and 5.03x respectively for CY10E and CY11E. The Net sales of the company are expected to grow at a CAGR of 12% over 2008 to 2011E. The company has plans to launch two vaccines Infanrix Hexa and Synflorix over the next two years. We recommend to **'BUY**' this stock at a target price of Rs.1925.00 for Medium to Long term gains.

(KPO Division Of Firstobject Technologies Ltd.)

Disclaimer:

This document prepared by our research analysts does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable but do not represent that it is accurate or complete and it should not be relied on as such. Firstcall India Equity Advisors Pvt. Ltd. or any of it's affiliates shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This document is provide for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision.

Firstcall India Equity Research: Email – info@firstcallindia.com		
B. Harikrishna	Banking	
B. Prathap	IT	
A. Rajesh Babu	FMCG	
C.V.S.L.Kameswari	Pharma	
U. Janaki Rao	Capital Goods	
E. Swethalatha	Oil & Gas	
D. Ashakirankumar	Auto	
Kavita Singh	Diversified	
Nimesh Gada	Diversified	
Priya Shetty	Diversified	
Tarang Pawar	Diversified	
Neelam Dubey	Diversified	

Firstcall India also provides


Firstcall India Equity Advisors Pvt.Ltd focuses on, IPO's, QIP's, F.P.O's, Takeover Offers, Offer for Sale and Buy Back Offerings.

Corporate Finance Offerings include Foreign Currency Loan Syndications, Placement of Equity / Debt with multilateral organizations, Short Term Funds Management Debt & Equity, Working Capital Limits, Equity & Debt Syndications and Structured Deals.

Corporate Advisory Offerings include Mergers & Acquisitions(domestic and cross-border), divestitures, spin-offs, valuation of business, corporate restructuring-Capital and Debt, Turnkey Corporate Revival – Planning & Execution, Project Financing, Venture capital, Private Equity and Financial Joint Ventures

Firstcall India also provides Financial Advisory services with respect to rising of capital through FCCBs, GDRs, ADRs and listing of the same on International Stock Exchanges namely AIMs, Luxembourg, Singapore Stock Exchanges and other international stock exchanges.

For Further Details Contact: 3rd Floor,Sankalp,The Bureau,Dr.R.C.Marg,Chembur,Mumbai 400 071 Tel.: 022-2527 2510/2527 6077/25276089 Telefax: 022-25276089 E-mail: info@firstcallindiaequity.com www.firstcallindiaequity.com



(KPO Division Of Firstobject Technologies Ltd.)